Disease-modifying treatments for diabetic retinopathy
ThromboGenics is a global biotechnology company delivering innovative treatments for diseases of the back of the eye, with a focus on diabetic eye disease. Our first product, JETREA® (ocriplasmin), has been approved in 54 countries worldwide.
The company is strongly committed to R&D on treatments for diabetes-related eye diseases such as diabetic retinopathy (DR) and diabetic macular edema (DME). We recently launched a Phase II clinical trial with THR-409 (ocriplasmin) in diabetic retinopathy.
ThromboGenics is headquartered in Leuven, Belgium, with offices in Iselin, NJ (US) and Dublin, Ireland. The company is listed on the NYSE Euronext Brussels exchange under the symbol THR.
Oncurious: spinning out oncology project in joint venture
In April 2015, ThromboGenics chose to spin off its oncology research activities in a joint venture with VIB (Flanders Institute for Biotechnology). This new company, Oncurious NV, will focus on the development of innovative medicines for the treatment of pediatric brain tumors. The company plans a Phase I/IIa clinical trial with TB-403 for the treatment of medulloblastoma, a rare brain tumor that mainly affects children. First patient enrollment is expected towards the end of 2015.